Helping people in need !!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Take a listen .. GOOD LUCK LONGS
BJ Lehmann, President and COO of Athersys, reviews key design features for the pivotal #MultiStem stroke studies - TREASURE and MASTERS-2. pic.twitter.com/5DDcgKg60J
— Athersys Inc (@athersys) February 21, 2022
Take a listen regarding MultiStem Cell Therapy - Therapeutic Hypothesis ... GOOD LUCK LONGS
A look at Athersys stroke animation MultiStem MoA .. GOOD LUCK LONGS
Take a listen MultiStem Clinical Programs .. GOOD LUCK LONGS
X .. When Allllllll Medical & Pharma Events conventions happen, there's a list of topics from Multi Stem etc that will be presented. It's getting your brand out which convention are alllllll about. Look at the list of companies which it will last for the next couple of months. Athersys will be there to share .. GOOD LUCK LONGS
X .. Here's a list and YES they will be there .. GOOD LUCK LONGS
https://10times.com/neworleans-us/medical-pharma
Yes, the presentation wasn't bad ARDS etc is STILL full steam ahead. Master's trial should be completed sometime this year. Regards to the impending Healios trial hopefully be next month or two. So they are still talking with the partner from last year and other big pharma companies which is Good news. According to them, their are some parties of interest in Europe, but who knows what the deal is on the horizon. I think it could be 1 of 2 things Hardy made a deal to nix the initial GVB partner and of course get rid of Gil, but Hardy got them to agree to give him a chance to get the ball rolling in Japan. Now if that fails that would amenable to a European partner and they know and believe the product works. There's a BIG medical conference in New Orleans next week that should be interesting .. GOOD LUCK LONGS
The price will ALWAYS be ahead of the NEWS COMING when they make their presentation on its MultiStem clinical programs. The company is due to present an outlook of its ischemic stroke program, including perspectives on the upcoming Phase 2/3 TREASURE data readout. The study is evaluating over 200 stroke patients. They will also present clinical data from the MultiStem acute respiratory distress syndrome program, including data from both the MUST-ARDS and the ONE-BRIDGE clinical trials. Reflecting on the combined clinical data and supporting information, the company's management will provide its outlook for MultiStem for the treatment of ARDS and its plans for moving the program forward ... GOOD LUCK LONGS
Just when your about to enjoy your weekend, they sneak in a rally ... GOOD LUCK LONGS
https://www.reddit.com/r/ATHX/comments/rylu9w/167000_shares_traded_after_hours_on_a_friday/?%24deep_link=true
Plenty of inside buying has happened .... GOOD LUCK LONGS
https://t2biosystems.gcs-web.com/financial-information/sec-filings
This should be interesting for ALLLLL they WILL be Working the crowd…. GOOD LUCK LONGS
https://www.jpmorgan.com/solutions/cib/insights/health-care-conference
This should be interesting for ALLLLL they WILL be Working the crowd…. GOOD LUCK LONGS
https://www.jpmorgan.com/solutions/cib/insights/health-care-conference
Short interest decreased by 6% to 16,423,606 from 17,534,122. Short percentage of the float remains unchanged at 8% from prior reporting date ... GOOD LUCK LONGS
Healios has entered into a joint research agreement with the Department of Gastroenterological and Transplant Surgery (Prof. Hideki Ohdan), Graduate School of Biomedical and Health Sciences, Hiroshima University, to advance HLCN061 for hepatocellular carcinoma .. GOOD LUCK LONGS
Healios has entered into a joint research agreement with the Department of Gastroenterological and Transplant Surgery (Prof. Hideki Ohdan), Graduate School of Biomedical and Health Sciences, Hiroshima University, to advance HLCN061 for hepatocellular carcinoma.
— Dr. Tadahisa "Hardy" Kagimoto, MD 鍵本 忠尚 (@HardyTSKagimoto) December 21, 2021
BARDA on Twitter: "DRIVe seeks partners to develop host-directed therapeutics for acute respiratory distress to improve long-term outcomes. These #MedicalCountermeasures could aid in the current #pandemic or future #HealthSecurity emergencies. Application
DRIVe seeks partners to develop host-directed therapeutics for acute respiratory distress to improve long-term outcomes. These #MedicalCountermeasures could aid in the current #pandemic or future #HealthSecurity emergencies. Application & more info: https://t.co/Cd002pPXsY pic.twitter.com/5CWkYZ7xxM
— BARDA (@BARDA) December 17, 2021
The discussion continues ... GOOD LUCK LONGS
https://www.reddit.com/r/ATHX/comments/r9dztq/mhlw_raises_alert_on_myocarditis_as_serious/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
https://www.reddit.com/r/ATHX/comments/r8s70f/extreme_exercise_linked_to_stroke/?%24deep_link=true&correlation_id=12d425d0-f27b-4630-9dc6-c790287bff29&post_fullname=t3_r8s70f&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_body&utm_medium=Email+Amazon+SES&_branch_referrer=H4sIAAAAAAAAA22QzWrDMBCEn8a9%2BaeSayeFUAKl9AF66E3I0toR0R%2FSGrtv31XS3AoSGr5hZhddEGN%2BbdsEWhtsZIyNNf7a8vhWsZ7HEwiZn0iGZBbjpRVrsqdLSVX8XLEPOtu2NX95FRyBRPf89flNDwEHHnOhhzx2MwnYMYEDATskZTKIMhG0wCAypnCFUsupudcA8eZW%2FB3TSsagQkpgJZrghdHEn5nu2Yvu6pmNU90PvKuPWg21Go8dO4zTPLMj5WLIKObVWi8dlDouHgvdPeM17KWPQIKZFDhprNBmgYx3KJR0UZrF%2F%2B%2FmsCYFD4%2Fgik6o4JF%2BgOhtzBT0zy8q%2F2CIdQEAAA%3D%3D&%243p=e_as&_branch_match_id=902620434927026485
More potential for T2 as different new panels use blood samples for detecting additional disease like cancer.
This looks like a trend speeding up for the use of blood samples to detect more and more disease types .. GOOD LUCK LONGS
https://www.yahoo.com/gma/detecting-cancer-simple-blood-draw-100044361.html
T2 confirmed the year end goals, talked about long term means to lower costs and the move to Billerica, increased orders from Barda, shortened R&D deadlines for Barda projects ... It sounds like we are on the right path .. GOOD LUCK LONGS
Decent volume today on the uptick over 1 million traded and it penetrated overhead resistance at $1.40 --1.42 twice ..I think the BARDA support may be in play. Treatment, rather than vaccine, or in conjunction with vaccine is the way to go. In the past, it was pointed out to me that a condition of the Barda support, a company must be able to prove that they are capable of mass production, at or before the grant. This further explains the bold step taken to build out the Stow Expansion in manufacturing. This would help qualify the company for the grant ... GOOD LUCK LONGS
Stock is up today, due to Reddit post indicating Barda alive again.
Change in the gov approach to Covid-- to include treatment----
consideration given to companies that provide treatment.
I have always felt that the companies starting manufacturing plants before FDA approval was an indication that BARDA had informed the firm that being able to manufacture in size was a condition of their suitability for funding. It makes sense, but that just my logical thinking, which is not what you expect from our gov now a days ... GOOD LUCK LONGS
Mutual funds are most usually on an October fiscal year. This is done so that they can reach out to shareholders with results by the end of the year. They often sell their unrealized losses to show holdings that are at current prices above cost. This is called window dressing.
Individuals often start tax loss selling OCT, NOV to get a jump on end of year decisions. Could start even in Sept, for quarterly filers. Once the stock broke support at approx $1.40 , it was suspect to reach $1.00. The management team has not delivered, performed, accomplished. They are being known as good talkers but not doers. All of this causes despair in the minds of ATHX investors, and when the rest of the market was good, some don't hesitate to cover gains with existing paper losses.
This distortion in price to value, is not manipulation as many have guessed, but rather movement of high beta equities. Does the future hold promise, potential favorable events??? YES. New CEO to steer a rudderless ship. Approval in Japan, soon--maybe. Trials results, here and abroad. Sale of licenses for sales in Europe and elsewhere. Sale of the company. Friendly, or tender offer. It ain't over, the stock is acting like a company with no future possibilities, this is not true, as illustrated above. STRONG HANDS PREVAIL, seems to be the right course of action .. GOOD LUCK LONGS
LEXINGTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Singapore and South Korea. Under the terms of the agreements, T2 Biosystems will sell T2Dx(R) Instruments, along with T2Bacteria(R) , T2Candida(R) and T2Resistance(R) Panels through these distributors.
The execution of these exclusive distribution agreements marks T2 Biosystems' entry in the Asia-Pacific market. According to the Asia Pacific Sepsis Alliance, the estimated national sepsis incidences in this region ranges from 120 up to 1,600 per 100,000(1) . Together, T2 Biosystems and its new distribution partners are collaborating with health authorities in Singapore and South Korea to gain regulatory approvals and offer patients the highest quality sepsis care available, beginning with a purchase of two T2Dx Instruments that was shipped to Singapore in September and a purchase order for four T2Dx Instruments to be shipped to South Korea by year-end ... GOOD LUCK LONGS